Vol.

No.

June 19, 2020Jun 19, 2020

Free

DOWNLOAD THE PDF

Sharpless: COVID-19 expected to increase mortality by at least 10,000 deaths from breast and colorectal cancers over 10 years

Cover Story

COVID-19 & Cancer Free NCI

Sharpless: COVID-19 expected to increase mortality by at least 10,000 deaths from breast and colorectal cancers over 10 years

By Matthew Bin Han Ong

The COVID-19 pandemic will likely cause at least 10,000 excess deaths from breast cancer and colorectal cancer over the next 10 years in the United States.

COVID-19 & Cancer Free

ACS faces precipitous drop in fundraising
Uncertainty surrounds fall round of grants

By Paul Goldberg

COVID-19 & Cancer Free Guest Editorial

Conquest of COVID-19: Publish it to death?

By Robert Peter Gale

Clinical Free Trials & Tribulations

Mobile pharmacies—driving down rural cancer care disparities

By Justin Floyd, James L. Wade III and Allison Braden

COVID-19 Updates

FDA joins Reagan-Udall, Friends of Cancer Research to form COVID-19 Diagnostics Evidence Accelerator

Research!America seeks $26 billion boost to NIH, CDC, FDA funding in FY21

Algorithm helps select breast cancer patients for urgent surgery or chemotherapy during pandemic

FDA issues warning letters to companies marketing antibody tests

TERAVOLT registry tracks outcomes of treatments among thoracic cancer patients with COVID-19

Immunotherapy clinical trial for COVID-19 open at Mount Sinai

In Brief

Siteman Cancer Center earns highest NCI rating

MSK's Charles L. Sawyers named AACR Academy president-elect

Postow, Merea, named to new positions at MSK

Kunle Odunsi named SITC board member

Glenn D. Steele Jr. named chair of City of Hope board of directors

David Cortez named associate director of basic science research at VICC

Jessica Karen Wong joins Fox Chase

OSUCCC – James Cancer Diagnostic Center speeds up diagnosis, treatment

Roswell Park dermatology expert Oscar Colegio dies at 47

Clinical Roundup

LLS, NCI and Children's Oncology Group collaborate on global master clinical trial for acute leukemia

Research and framework for genetic testing in prostate cancer supports broader use of panels, testing in early stage disease

Berzosertib shows promise in first clinical trial

Tecentriq improves response rate in early TNBC

ACE-CL-001, ASCEND trials demonstrate long-term efficacy and tolerability of Calquence in CLL

Blood test to monitor cancer is up to 10 times more sensitive than current methods

Drugs & Targets

Keytruda receives second biomarker-based indication from FDA, regardless of tumor type

FoundationOne CDx receives FDA approval as companion diagnostic with Keytruda

Lurbinectedin receives accelerated approval by FDA for metastatic SCLC

Gemtuzumab ozogamicin receives extended indication for CD33-positive AML in pediatric patients

City of Hope signs licensing agreement with Scopus BioPharma to develop novel, targeted IO gene therapy

Royal Philips and MD Anderson to facilitate personalized oncology treatments and clinical trial matching based on genomic markers

Isoray, University of Cincinnati physicians company sign research agreement to study head and neck cancers

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 46 - December 19, 2025